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Background. Retroperitoneal tumours propagate intrathoracic caval tumour thrombi (ICTT) of which we consider two subgroups:
ICTT-III (extracardiac) and ICTT-IV (intracardiac). Methods. Case series review. Results. 29 series with 784 patients, 453 with
extracardiac and 331 with intracardiac ICTT. Average age was 59 years. 98% of the tumours were RCC, 1% adrenal and Wilms’
tumours, and 1% transitional cell carcinomas. The prevalent incision was rooftop with or without sternotomy. Mortality was 10%
(5% for ICTT-III, 15% for ICTT-IV).Morbidity was 56% (36% for ICTT-III, 64% for ICTT-IV) and reoperation for bleeding was the
commonest complication (14%).Mean Blood loss was 2.6 litres for ICTT-III and 3.7 litres for ICTT-IV.Mean blood product use was
2.4 litres for ICTT-III and 3.5 litres for ICTT-IV. Operative and anaesthetic times exceeded 5 hours. Hospital stay averaged 13 days.
Variations in perioperative care included preoperative embolisation, perioperative transoesophageal echo, surgical incisions, and
extracorporeal circulation. Brief Summary. Surgery for ICTT has high transfusion, operating/anaesthetic time, and in-hospital stay
requirements, and intracardiac ICTT also attract higher risk. Preoperative tumour embolisation is controversial.The cardiothoracic
teamoffers proactive optimisation of blood loss and preemptivemanagement of intracardiac thrombus impaction: we should always
be involved in the management the ICTT.
1. Introduction
Tumour thrombus, as opposed to bland (i.e., blood) throm-
bus, is a collective term for intravascular metastases with
thrombotic elements. Tumour thrombi propagate in the
Inferior Vena Cava (IVC) from retroperitoneal primaries
such as renal cell carcinoma (RCC). 10% of the 50,000
RCC diagnosed internationally every year [1] present with
IVC thrombosis [2]. Similar caval tumour thrombi are
found in less common retroperitoneal primaries such as
Wilms’ tumour [3] and various adrenal, uterine, and bladder
tumours.The Levels of tumour thrombi have been defined by
Neves and Zincke of Mayo Clinic [4].
Level I, extension into the renal vein;
Level II, extension into the infrahepatic IVC;
Levels III, IVC, extension to the level of hepatic veins
but below the diaphragm; and
Levels IV, IVC, extension above the diaphragm and
into the right atrium or beyond.
This classification (not to be confusedwith theMAYOscoring
system for metastases) has been more or less established in
the literature with small minutiae in definitions [5–8].
Aggressive surgical resection has been the treatment of
choice. In RCC, this usually necessitates radical ipsilateral
nephrectomy [4–16].
As a whole, the management from the general and
urological points of view has recently been reviewed [6, 7,
9], yet the role of the cardiothoracic team can be further
discussed specifically in the 1% that tumour thrombi extend
into the intrathoracic (supradiaphragmatic and suprahepatic)
IVC [2].
These intrathoracic caval tumour thrombi (ICTT) pose
an even more complex surgical problem [5].
In search of anatomical boundaries to guide the complex
bicoelomic radical resection, we consider hereby two ICTT
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Table 1: Intrathoracic Caval Tumour Thrombi, cumulative periop-
erative data from 29 series: Apart from the numbers of ICTT-III and
ICTT-IV, values are average.
Total ICTT-III ICTT-IV
N 784 453 331
Age 59 52 56
Gender
Male 62% 70% 53%
Female 38% 30% 43%
Primary Tumour Side
Right 64% 76% 54%
Left 36% 24% 46%
Histology
Renal Cell Carcinoma 98% 99% 98%
Wilms or, Adrenal 1% 1% 1%
Transitional L Cell Carcinomas 1% 0% 1%
Pre-embolisation strategies 29% 22% 30%
Echo studies 88.50% 83.50% 89%
Incision
Midline Laparotomy 11% 16% 2%
Midline Laparotomy
+ Sternotomy 26% 20% 38%
Thoracoabdominal 3% 4% 6%
Chevron 34% 51% 8%
Chevron + Sternotomy 27% 9% 46%
IVC Resection and graft 12% 5% 19%
IVC clamps
Partial 22% 22% 21%
Complete 57% 71% 32%
Piggy-back’ Liver 62% 72% 40%
Pringle Manoeuver 59% 60% 40%
Perfusion Strategies
None 51% 84% 12%
Cardiopulmonary Bypass
without Arrest 44% 10% 84%
Circulatory Arrest 35% 10% 59%
Venous bypass 5% 6% 4%
Cardiopulmonary Bypass times 103min 88min 106min
Circulatory Arrest times 25min 23min 26min
Procedure duration 358min 339min 378min
Anaesthesia time 362min 331min 396min
Estimated blood Loss 3190mL 2665mL 3724mL
Volume of Transfusion 3142mL 2404mL 3548mL
Mortality 10% 5% 15%
Morbidity 56% 36% 64%
Haemorrhage and reoperation 14% 9% 26%
Deep venous Thrombosis 2% 1% 1%
Pulmonary Embolism 3% 2% 5%
Myocardial Infarction 1% 3% 0
Dysrhythmias 2% 2% 2%
Abdominal complications 5% 10% 6%
Table 1: Continued.
Total ICTT-III ICTT-IV
Sepsis/Infectious complications 4% 4% 6%
Acute Renal Failure 4% 4% 6%
Any other complications 3% 4% 5%
Length of Hospital Stay 13 14 13
subgroups mirroring the Levels III and IV of the compre-
hensive “Neves and Zincke” classification [4]: ICTT-III and
ICTT-IV, respectively.
We sought the perioperative evidence on ICTT surgery
with curative intent. We reflected on relevant data as we
sought to define the role of the cardiothoracic surgeon as a
member of the multidisciplinary team.
2. Materials and Methods
Ethical issues were not raised; therefore, ethical approval was
not sought. Absence of conflict of interest is declared.
2.1. PubMed Search. For clinical studies with at least 10
patients published between 1965 and March 31, 2011 in
English, search keywords “cava∗” AND “bypass” AND
“nephrectomy” were limited to “human subjects.” Articles
were also identified using the function “related articles” in
PubMed and cross-validated by hand search so that over-
lapping cohorts were appropriately merged. We reanalysed
pooled data from these studies. The data were thus tabulated
(Table 1) in order to formulate our cohortial endpoints.
2.2. Perioperative Considerations
(i) Imaging.
(a) Echocardiography: in addition to abdominal
ultrasound (standard imaging modality for
RCC), nine tenths of the cohort had pre- or
perioperative cardiac ultrasound (echo) with
an increasing use of transoesophageal modality
(TOE or TEE). The benefit from TOE is real-
time assessment of potentially mobile tumour
thrombi in risk of intracardiac impaction, when
preemptive use of extracorporeal perfusion is
indicated.
(b) Embolisation of the (renal) tumour through
angiography/cavography. The embolisation ai-
ms primarily to limit vascularity and thence
haemorrhage upon surgical dissection and
decrease the engorged renal hilum [6].
(ii) Surgical access and incisions [5].
Incisions were abdominal and thoracic. The original
approaches were based on midline laparotomy or
chevron (roof-top, bilateral Kocher) incisions afford-
ing only transdiaphragmatic access to the IVC and
right atrium [10]. Later in the series, abdominal
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incisions were combined with sternotomy or thora-
cotomy. This involved the cardiothoracic surgeon the
preoperative planning.
(iii) Cavotomy and reconstruction of the IVC.
The perioperativemanagement of the IVC is based on
principles influenced by hepatic transplantation [6]:
resectionwith curative intent, avoidance of narrowing
the lumen, and control of the tumour thrombus. It is
evident that the options are
(a) cavotomy and direct closure, where 50% of the
lumen can be preserved [6];
(b) patch closure or resection with interposition
graft.
Occasionally, the IVC lumenhas been surgically oblit-
erated, yet this option is rather dated andnot routinely
used. IVC Filters are used in circumstances of growth
occluding the lumen and history of proximal emboli
[6]. Sequential clamping of the IVC [8] may lead
to hypotension, managed (in the absence of CPB)
with preemptive Trendelenburg position and liberal
volume expansion.
(iv) Surgical bleeding and transfusion requirements.
Extensive retroperitoneal dissection and cardiovas-
cular sub procedures predispose to considerable
bleeding, especially from engorged collateral phrenic
veins. The management of intravascular volume is
paramount to a favourable outcome (see also the pre-
vious paragraph on IVC clamping). It also accounts
for the considerable perioperative transfusions [10].
(v) Use of perfusion techniques.
(vi) Mortality.
(vii) Morbidity.
(viii) Length of hospital stay.
3. Results and Analysis (Table 1)
29 series [2, 8, 10–36] with 784 patients from the last four
decades offer cumulated perioperative data; 453 cases of
ICTT-III and 331 of ICTT-IV were scrutinised. We included
follow-up papers with the understanding that although their
focus veered away from the perioperative period, their data
for surgery were relevant to our review.
3.1. Demographics. Average age at operation was 59 years.
62% of the patients were male. 98% tumours were RCC. The
remaining were Wilms’, adrenal, and bladder tumours. 64%
of primaries were in the right side, 36% on the left. There
were no primary tumours from the anatomical midline. The
laterality of tumour is relevant to operative planning as a left
sided tumour presents a different pathological anatomy of the
thrombus and the necessary intraabdominal dissection.
3.2. Imaging. It is paramount to determine the extent of
the IVC growth in order to plan the bicoelomic access and
dissection [6, 37]. 29% of patients had had preoperative
tumour embolization via cavography as ameasure to decrease
the tumour burden and, importantly for the surgical team,
reduce the expected blood loss by rending the culprit primary
lesion and the organ (in 98% cases the kidney) relatively
avascular. The contrast cavogram affords also a preoperative
assessment of the extension of the thrombus.
3.3. Surgical Access and Incisions. The prevalent access was
that of chevron (rooftop) incision with (27%) or without
(34%) sternotomy.
37% of the patients were operated through the anatomical
midline and 11% just by a median laparotomy.
3% of patients had some form of lateral thoracoabdom-
inal incision. 86% of ICTT-IV had undergone sternotomy
in combination with chevron (46%) or midline laparotomy
(38%). The two teams operating on intracardiac extensions
without opening the chest are also the “champions” of
avoiding (albeit in small samples) CPB [10, 16].
The abdominal dissection has often been based on
controlling of the porta hepatis (Pringle manoeuvre, with
vascular loops under intermittent tension or soft vascular
clamps) and the dissection of the liver known as “piggy-back”
with minimal dissection of the IVC [10, 38].
3.4. Cavotomy and IVC Reconstruction. 12% of patients had
resection of IVC and interposition graft. 55% of patients had
a partial occlusion clamp on their preserved IVC, and 22%
had cross-clamping of the preserved IVC.
3.5. Perfusion. 51% of total cases had no use of any perfusion
technique (Table 1). We identified two extreme positions:
nonuse in two small series [16, 25] and absolute indication
[14, 20].
There was variability in most setups. Most surgeons
retorted to invest in the (presumed expensive) perfusion tech-
niques for ICTT-IV [11]; 88% of these intracardiac cases were
operated with some form of bypass, reflecting the incidence
of sternotomy in this subgroup. Moreover, circulatory arrest
was used in 60%of ICTT-IVwhilst in only 10%of ICTT-III. A
small number of patients (5%) had only veno-venous bypass.
Average cardiopulmonary bypass time was 103 minutes
(88 minutes for ICTT-III and 106 minutes for ICTT-IV).
HCA times averaged 25 minutes (23 in ICTT-III and 26 in
ICTT-IV).
3.6. Operating and Anaesthetic Times. The former average
was 352 and the latter 362 minutes. The respective times
for each subgroup were 339/331 minutes for ICTT-III and
378/396 minutes for ICTT-IV. We comment on these data.
3.7. Blood Loss and Transfusions. The magnitude of the
operations can be appreciated by the considerable average
blood loss and transfusion volumes: 2.6 L of blood loss and
2.4 L of blood products for ICTT-III and 3.7 L of blood loss
and 3.5 L of blood products for ICTT-IV (Table 1).
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3.8. Mortality. This was 10% (5% for ICTT-III and 15% for
ICTT-IV).
3.9. Morbidity. Any-or-none morbidity was 56% (36% for
ICTT-III, 64% for ICTT-IV). Most common complications
were related either to perioperative bleeding (and reexplo-
ration) or thromboembolism (Table 1). Incidence of acute
renal failure was 4%.
3.10. Length of Hospital Stay. That was 13 days. This is an
important outcome measure that has to be weighed against
variation of health policies and balance of tertiary to primary
care worldwide.
4. Discussion
Multidisciplinary surgery for ICTT is a formidable under-
taking that has elicited debate [38]. Resourcefulness [18] and
collaboration are essential.
The authorship of the various series includes primar-
ily noncardiothoracic surgeons [6]. The ample literature is
skewed towards the urological/general surgical point of view,
and our paper aspires to balance this.
4.1. Choice of Incision and the Cardiothoracic Surgeon. The
contrast of opinion on choice of incision is germane to the
involvement of the cardiothoracic surgeon in ICTT. Incisions
vary between surgeons and relate to the extracardiac or
intracardiac level of thrombus [22, 27, 30, 31, 33]. The debate
is akin to that of en bloc or trans hiatal oesophagectomies.
The abdominal approach has a lot in common with hepatic
transplantation [10]. The risk of cardiac impaction of throm-
bus during such transdiaphragmatic procedures, especially
during the manoeuvres of “milking” the IVC retrogradely
[10], has in fact led to earlier involvement of cardiotho-
racic surgeons; a thoracic incision preempts the need for
intracardiac disimpaction of tumour thrombus [39]. It is
noted that the two teams reporting no CPB whatsoever have
small total numbers and only four patients with ICTT-IV. It
was expected that most surgeons would consider perfusion
for all the ICTT-IV [11] and some ICTT-III [8], especially
where preoperative imaging could not exclude intracardiac
thrombus. It is evident that assessment of the cranial extent
of the thrombus by preoperative imaging can be inaccurate
[40–43]. It follows that preemptive involvement of the cardio-
thoracic specialists, including anaesthetists and perfusionists,
is prudent, especially where they are not available on site.
The sternotomy offers the facile option of central can-
nulation for cardiopulmonary bypass with either of Ross
basket, “two-stage,” or bicaval cannulation depending on
preference and extend of thrombus. The peripheral (femoral
or axillary [9]) cannulation is of course available when there
are concerns for the extent of thrombus around the possible
IVC cannulation areas. Preemptive hypothermic circulatory
arrest [13] necessitates sternotomy. CPB can, according to one
well-presented school of thought [23], only be avoided with
caution in the presence of a free-floating thrombus.
That is how the risk of intraoperative tumour emboliza-
tion (that has being reported as cause of death [28, 30]) is
managed efficiently. The Sloan-Kettering group had previ-
ously pursued a very well described transabdominal tech-
nique [16], possibly because of the limited access to inhouse
cardiac surgery, yet they have changed recently.
We note that the HCA times were reasonable and no
HCA-attributable incidents were recorded in any of the
subjects. Of note also is the potential of HCA to create a
“bloodless field” of dissection [8] and facilitate the intra-
atrial manoeuvring of the thrombus in relation to the outflow
cannula.
4.2. Blood Conservation. We further note the need ofmassive
transfusions (replacement of body blood volume in 24 hours
or half of blood volume in 4 hours). Heparinisation for
CPB, even after completing the abdominal dissection [38],
would account for the 26% bleeding morbidity in ICTT-
IV, where CPB was used in almost 9 out of 10 patients.
On the other hand, the cost and implications could drive a
reexpansion of the indications of aprotinin [44] or utilising
tranexamic acid [45]. By the same token, cell saving tech-
niques will be of relevance; some of the shed blood can be
returned to the patient through the Intraoperative perfusion
circuit or the cell saver apparatus. Procoagulant and blood
conservation strategies, including biological and synthetic
glues, may reduce the need for transfusion; the patients’
intact immunocompetence is important in the primary diag-
nosis of malignancy. The presence of an anaesthetic team
with experience in cardiovascular anaesthesia is essential
[10].
4.3. Preoperative Embolisation. Stark contrasting on opinions
is noted [46–48]. Its strong critics [47] proffer nonran-
domised retrospective data of two groupswith 30%difference
in presence of ICTT. There is one propensity-matched study
in favour of embolisation [48]. This technique also relates
inversely to use of preemptive HCA. We note the emerging
capabilities of diffusion weighted magnetic resonance, espe-
cially in accurate definition of the level and nature of the
thrombotic lesions [49].
4.4. Morbidity and Mortality. Complications are to be
expected in more than half of patients. We found that
morbidity and mortality varied between lower and higher
levels of tumour; intracardial extension rends surgery three
times riskier, yet tumour extension has not always been found
to affect long-term survival [32, 35, 50]. Acute renal failure
and renal support appear as a relatively rare complication,
given that 98% of patients had a nephrectomy and three out
of ten had their left cancerous kidney removed.
The times recorded indicate long procedures (exceeding 5
hours in average) and also unveiling a weakness in recording
operating and anaesthetic times; these appear similar instead
of at least 30 minutes difference, affording time for anaes-
thetic induction and insertion of multiple monitoring lines
[7].
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5. Conclusions
Close multidisciplinary collaboration has led to acceptable
operative risks for ICTT. We propose that it is achieved more
efficiently in hospitals with on-site cardiothoracic teams. We
consider the following advantages of such policy:
(i) management of blood loss, with the expertise in
preempting and correcting the circulatory events
inevitable to such extensive cardiovascular proce-
dures and haemostasis, with experience in all aspects
of adjuncts (glues and other technologies [45]),
(ii) risk management of fracture thrombi [39], with the
advantage of preemptive extracorporeal perfusion.
A standard of care for ICTT is emerging. The cardiothoracic
surgeon is increasingly involved [19, 37] were previously
excluded from their management [10, 16, 51]. We believe
that preemptive cardiothoracic consultation is instrumental
in developing such standard of care. In the United Kingdom,
the National Institute for Clinical Excellence has already
mandated the preemptive referral to the cardiothoracic team
for all ICTT in at least one region (toWythenshawe Hospital,
Manchester, UK). A streamlined procedure plan would be
especially advantageous if technical performance was to be
scored [52] in order to convince the stakeholders where the
local setup is reluctant to change [16]; a marginal analysis
[53] would recommend reallocating resources to increase
efficiencies.
6. Limitations
Retrospective reviews have to be interpreted cautiously;
limitations have been previously outlined in a small self-
reporting multicentre review of ICTT-IV [16].
We further note that potential causes of bias are
(i) reporting bias
(ii) control for comorbidities, which influence mortality
and unbalance any attempt to compare interventions,
(iii) missing variables, especially in relation with the
morbidity,
(iv) nonuniformdefinition of complications between cen-
tres [23], and
(v) lack of detailed perioperative patient information for
series that focus on followup rather than the surgery
itself.
Acknowledgment
The corresponding author is grateful to Mr. Keith Buchan
FRCS,ConsultantCardiothoracic Surgeon,North of Scotland
Cardiothoracic Unit, United Kingdom, for valuable input
in the clinical and academic minutiae of the operative
techniques.
References
[1] L. Lipworth, R. E. Tarone, and J. K. McLaughlin, “The epidemi-
ology of renal cell carcinoma,” The Journal of Urology, vol. 176,
no. 6, pp. 2353–2358, 2006.
[2] F. F. Marshall, D. D. Dietrick, W. A. Baumgartner, and B.
A. Reitz, “Surgical management of renal cell carcinoma with
intracaval neoplastic extension above the hepatic veins,” The
Journal of Urology, vol. 139, no. 6, pp. 1166–1172, 1988.
[3] A. Lall, K. Pritchard-Jones, J. Walker et al., “Wilms’ tumor with
intracaval thrombus in the UK Children’s Cancer Study Group
UKW3 trial,” Journal of Pediatric Surgery, vol. 41, no. 2, pp. 382–
387, 2006.
[4] R. J. Neves and H. Zincke, “Surgical treatment of renal cancer
with vena cava extension,” British Journal of Urology, vol. 59, no.
5, pp. 390–395, 1987.
[5] A. Vaidya, G. Ciancio, andM. Soloway, “Surgical techniques for
treating a renal neoplasm invading the inferior vena cava,”The
Journal of Urology, vol. 169, no. 2, pp. 435–444, 2003.
[6] F. Pouliot, B. Shuch, J. C. Larochelle, A. Pantuck, and A. S.
Belldegrun, “Contemporary management of renal tumors with
venous tumor thrombus,”The Journal of Urology, vol. 184, no. 3,
pp. 833–841, 2010.
[7] S. M. Lawindy, T. Kurian, T. Kim et al., “Important surgical
considerations in the management of renal cell carcinoma
(RCC) with inferior vena cava (IVC) tumour thrombus,” BJU
International, vol. 110, no. 7, pp. 926–939, 2012.
[8] J. C. Nesbitt, E. R. Soltero, C. P. N. Dinney et al., “Surgical
management of renal cell carcinoma with inferior vena cava
tumor thrombus,” Annals of Thoracic Surgery, vol. 63, no. 6, pp.
1592–1600, 1997.
[9] C. Wotkowicz, J. A. Libertino, A. Sorcini, and A. Mourtzinos,
“Management of renal cell carcinoma with vena cava and
atrial thrombus: Minimal access vs median sternotomy with
circulatory arrest,” BJU International, vol. 98, no. 2, pp. 289–297,
2006.
[10] G. Ciancio, A. S. Livingstone, and M. Soloway, “Surgical
management of renal cell carcinoma with tumor thrombus
in the renal and inferior vena cava: the university of miami
experience in using liver transplantation techniques,” European
Urology, vol. 51, no. 4, pp. 988–995, 2007.
[11] A. S. M. Ali, N. Vasdev, S. Shanmuganathan et al., “The surgical
management and prognosis of renal cell cancer with IVC
tumor thrombus: 15-Years of experience using a multi-specialty
approach at a single UK referral center,”Urologic Oncology, 2011.
[12] M. Al Otaibi, T. A. Youssif, A. Alkhaldi et al., “Renal cell
carcinoma with inferior vena caval extention: impact of tumour
extent on surgical outcome,” BJU International, vol. 104, no. 10,
pp. 1467–1470, 2009.
[13] M. Ayati, A. Nikfallah, P. Jabalameli, T. V. Najjaran, M. Noroozi,
and H. Jamshidian, “Extensive surgical management for renal
tumors with inferior vena cava thrombus,” The Journal of
Urology, vol. 3, no. 4, pp. 212–215, 2006.
[14] B. Chiappini, C. Savini, G. Marinelli et al., “Cavoatrial
tumor thrombus: single-stage surgical approach with profound
hypothermia and circulatory arrest, including a review of the
literature,” Journal of Thoracic and Cardiovascular Surgery, vol.
124, no. 4, pp. 684–688, 2002.
[15] M. Jibiki, T. Iwai, Y. Inoue et al., “Surgical strategy for treating
renal cell carcinoma with thrombus extending into the inferior
vena cava,” Journal of Vascular Surgery, vol. 39, no. 4, pp. 829–
835, 2004.
6 ISRN Vascular Medicine
[16] M. G. Kaag, C. Toyen, P. Russo et al., “Radical nephrectomy
with vena caval thrombectomy: a contemporary experience,”
BJU International, vol. 107, no. 9, pp. 1386–1393, 2011.
[17] M. S. Kalkat, A. Abedin, S. Rooney et al., “Renal tumours
with cavo-atrial extension: surgical management and outcome,”
Interactive Cardiovascular andThoracic Surgery, vol. 7, no. 6, pp.
981–985, 2008.
[18] R. J. Karnes and M. L. Blute, “Surgery insight: management
of renal cell carcinoma with associated inferior vena cava
thrombus,” Nature Clinical Practice Urology, vol. 5, no. 6, pp.
329–339, 2008.
[19] J. G. Lubahn, A. I. Sagalowsky, D. H. Rosenbaum et al., “Con-
temporary techniques and safety of cardiovascular procedures
in the surgical management of renal cell carcinoma with tumor
thrombus,” Journal of Thoracic and Cardiovascular Surgery, vol.
131, no. 6, pp. 1289–1295, 2006.
[20] A. C. Novick, M. C. Kaye, D. M. Cosgrove et al., “Experience
with cardiopulmonary bypass and deep hypothermic circula-
tory arrest in the management of retroperitoneal tumors with
large vena caval thrombi,” Annals of Surgery, vol. 212, no. 4, pp.
472–477, 1990.
[21] D. J. Parekh, M. S. Cookson, W. Chapman et al., “Renal cell
carcinoma with renal vein and inferior vena caval involvement:
clinicopathological features, surgical techniques and outcomes,”
The Journal of Urology, vol. 173, no. 6, pp. 1897–1902, 2005.
[22] J. Parra, S. J. Drouin, V. Hupertan, E. Comperat, M. O. Bitker,
andM. Roupreˆt, “Oncological outcomes in patients undergoing
radical nephrectomy and vena cava thrombectomy for renal cell
carcinoma with venous extension: a single-centre experience,”
European Journal of Surgical Oncology, vol. 37, no. 5, pp. 422–
428, 2011.
[23] B. Shuch, P. L. Crispen, B. C. Leibovich et al., “Cardiopulmonary
bypass and renal cell carcinomawith level IV tumour thrombus:
can deep hypothermic circulatory arrest limit perioperative
mortality?” BJU International, vol. 107, no. 5, pp. 724–738, 2011.
[24] S. Yazici, K. Inci, C. Y. Bilen et al., “Renal cell carcinoma
with inferior vena cava thrombus: the Hacettepe experience,”
Urologic Oncology, vol. 28, no. 6, pp. 603–609, 2010.
[25] C. Yamashita, T. Azami, M. Okada et al., “Usefulness of
cardiopulmonary bypass in reconstruction of inferior vena cava
occupied by renal cell carcinoma tumor thrombus,” Angiology,
vol. 50, no. 1, pp. 47–53, 1999.
[26] A. Welz, N. Schmeller, C. Schmitz, B. Reichart, and A. Hof-
stetter, “Resection of hypernephromas with vena caval or
right atrial tumor extension using extracorporeal circulation
and deep hypothermic circulatory arrest: a multidisciplinary
approach,” European Journal of Cardio-Thoracic Surgery, vol. 12,
no. 1, pp. 127–132, 1997.
[27] G. J. Wang, J. P. Carpenter, R. M. Fairman et al., “Single-center
experience of caval thrombectomy in patients with renal cell
carcinoma with tumor thrombus extension into the inferior
vena cava,” Vascular and Endovascular Surgery, vol. 42, no. 4,
pp. 335–340, 2008.
[28] Y. Tsuji, A. Goto, I. Hara et al., “Renal cell carcinoma with
extension of tumor thrombus into the vena cava: surgical
strategy and prognosis,” Journal of Vascular Surgery, vol. 33, no.
4, pp. 789–796, 2001.
[29] J. R. Stewart, J. A. Carey, W. S. McDougal, W. H. Merrill, M. O.
Koch, and H. W. Bender Jr., “Cavoatrial tumor thrombectomy
using cardiopulmonary bypass without circulatory arrest,” The
Annals of Thoracic Surgery, vol. 51, no. 5, pp. 717–722, 1991.
[30] G. Staehler andD. Brkovic, “The role of radical surgery for renal
cell carcinoma with extension into the vena cava,” The Journal
of Urology, vol. 163, no. 6, pp. 1671–1675, 2000.
[31] F. Manassero, A. Mogorovich, G. Di Paola et al., “Renal cell
carcinoma with caval involvement: contemporary strategies of
surgical treatment,” Urologic Oncology, vol. 29, no. 6, pp. 745–
750, 2011.
[32] T. Klatte, A. J. Pantuck, S. B. Riggs et al., “Prognostic factors
for renal cell carcinoma with tumor thrombus extension,” The
Journal of Urology, vol. 178, no. 4, pp. 1189–1195, 2007.
[33] D. C. Vergho, A. Loeser, A. Kocot, M. Spahn, andH. Riedmiller,
“Tumor thrombus of inferior vena cava in patients with renal
cell carcinoma-clinical and oncological outcome of 50 patients
after surgery,” BMC Research Notes, vol. 5, p. 5, 2012.
[34] P. Sweeney, C. G. Wood, L. L. Pisters et al., “Surgical manage-
ment of renal cell carcinoma associated with complex inferior
vena caval thrombi,” Urologic Oncology, vol. 21, no. 5, pp. 327–
333, 2003.
[35] A. Haferkamp, P. J. Bastian, H. Jakobi et al., “Renal cell
carcinoma with tumor thrombus extension into the vena cava:
prospective long-term followup,”TheJournal ofUrology, vol. 177,
no. 5, pp. 1703–1708, 2007.
[36] J. Rigaud, J.-F. Hetet, G. Braud et al., “Surgical care, morbidity,
mortality and follow-up after nephrectomy for renal cancer
with extension of tumor thrombus into the inferior vena cava:
retrospective study since 1990s,” European Urology, vol. 50, no.
2, pp. 302–310, 2006.
[37] C.Wotkowicz, M. F. Wszolek, and J. A. Libertino, “Resection of
renal tumors invading the vena cava,” Urologic Clinics of North
America, vol. 35, no. 4, pp. 657–671, 2008.
[38] D. I. Swierzewski, M. J. Swierzewski, and J. A. Libertino,
“Radical nephrectomy in patients with renal cell carcinoma
with venous, vena caval, and atrial extension,” The American
Journal of Surgery, vol. 168, no. 2, pp. 205–209, 1994.
[39] B. Shuch, J. C. Larochelle, T. Onyia et al., “Intraoperative throm-
bus embolization during nephrectomy and tumor thrombec-
tomy: critical analysis of the University of California-Los
Angeles experience,” The Journal of Urology, vol. 181, no. 2, pp.
492–499, 2009.
[40] P. Sharma, R. Kumar, H. Singh et al., “Imaging thrombus
in cancer patients with FDG PET-CT,” Japanese Journal of
Radiology, vol. 30, no. 2, pp. 95–104, 2012.
[41] N. Mollard and H. Liu, “Right atrial thrombus from renal
cancer,” Journal of Clinical Anesthesia, vol. 22, no. 6, pp. 484–
485, 2010.
[42] H. Takayama, T. Kinouchi, N. Meguro et al., “Renal vein
thrombosis misdiagnosed as a renal cell carcinoma with a
tumor thrombus in the inferior vena cava,” International Journal
of Urology, vol. 5, no. 1, pp. 94–95, 1998.
[43] P. J. Hallscheidt, C. Fink, A. Haferkamp et al., “Preoperative
staging of renal cell carcinomawith inferior vena cava thrombus
using multidetector CT and MRI: prospective study with
histopathological correlation,” Journal of Computer Assisted
Tomography, vol. 29, no. 1, pp. 64–68, 2005.
[44] D. Pagano, N. J. Howell, N. Freemantle et al., “Bleeding in
cardiac surgery: the use of aprotinin does not affect survival,”
Journal of Thoracic and Cardiovascular Surgery, vol. 135, no. 3,
pp. 495–502, 2008.
[45] J. Shi, G. Wang, H. Lv et al., “Tranexamic acid in on-pump
coronary artery bypass grafting without clopidogrel and aspirin
cessation: randomized trial and 1-year follow-up,”TheAnnals of
Thoracic Surgery, vol. 95, no. 3, pp. 795–802, 2013.
ISRN Vascular Medicine 7
[46] M. J. Schwartz, E. B. Smith, D. W. Trost, and E. D. Vaughan Jr.,
“Renal artery embolization: clinical indications and experience
from over 100 cases,” BJU International, vol. 99, no. 4, pp. 881–
886, 2007.
[47] V. S. Subramanian, A. J. Stephenson, D. A. Goldfarb, A. F.
Fergany, A. C. Novick, and V. Krishnamurthi, “Utility of
preoperative renal artery embolization formanagement of renal
tumors with inferior vena caval thrombi,”Urology, vol. 74, no. 1,
pp. 154–159, 2009.
[48] H. Zielinski, S. Szmigielski, and Z. Petrovich, “Comparison
of preoperative embolization followed by radical nephrectomy
with radical nephrectomy alone for renal cell carcinoma,”
American Journal of Clinical Oncology, vol. 23, no. 1, pp. 6–12,
2000.
[49] O. A. Catalano, G. Choy, A. Zhu, P. F. Hahn, and D. V. Sahani,
“Differentiation of malignant thrombus from bland thrombus
of the portal vein in patients with hepatocellular carcinoma:
application of diffusion-weighted MR imaging,” Radiology, vol.
254, no. 1, pp. 154–162, 2010.
[50] B. Wagner, J.-J. Patard, A. Me´jean et al., “Prognostic value of
renal vein and inferior vena cava involvement in renal cell
carcinoma,” European Urology, vol. 55, no. 2, pp. 452–460, 2009.
[51] R. Ayyathurai, M. Garcia-Roig, M. A. Gorin et al., “Bland
thrombus association with tumour thrombus in renal cell
carcinoma: analysis of surgical significance and role of inferior
vena caval interruption,”BJU International B, vol. 110, pp. E449–
E455, 2012.
[52] M. Nathan, J. M. Karamichalis, H. Liu et al., “Surgical tech-
nical performance scores are predictors of late mortality and
unplanned reinterventions in infants after cardiac surgery,”The
Journal of Thoracic and Cardiovascular Surgery, vol. 144, no. 5,
pp. 1095.e7–1101.e7, 2012.
[53] A. Tsourapas and E. Frew, “Evaluating ’success’ in programme
budgeting and marginal analysis: a literature review,” Journal of
Health Services Research and Policy, vol. 16, no. 3, pp. 177–183,
2011.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
International Journal of
Endocrinology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
BioMed Research 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
PPAR
Resea rch
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Parkinson’s Disease
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
